SAMSUNG-SEMICONDUCTOR
15.9.2020 11:02:12 CEST | Business Wire | Press release
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced four new Samsung ISOCELL image sensors for its 0.7 micrometer (μm)-pixel product lineup; 108-megapixel (Mp) ISOCELL HM2, 64Mp ISOCELL GW3, 48Mp ISOCELL GM5 and 32Mp ISOCELL JD1. With the new 0.7μm ISOCELL technology, Samsung plans to expand the ultra-high-resolution offerings to mainstream smartphones.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200915005521/en/
“Samsung continues to pioneer innovations, such as ISOCELL Plus and Smart ISO, to deliver more pixels in a smaller package,” said Yongin Park, executive vice president of the sensor business at Samsung Electronics. “Last year, Samsung introduced the industry’s first 0.7μm-pixel image sensor and the first 108Mp sensors. Now we are bringing more of the advanced pixel technologies to mobile cameras in a variety of options that will enable high-resolution images and sleeker designs in a wider selection of tomorrow’s mobile devices.”
For ultra-high-resolution image sensors, even a mere 0.1μm-difference per pixel can have a significant impact on the overall size of the sensor as well as the height of the camera module. With pixels at 0.7μm, Samsung’s newest image sensors are up to 15-percent smaller than the 0.8μm sensors of the same resolution and reduce the height of the camera module by up to 10 percent. Smaller form factors give smartphone manufacturers more flexibility, such as added features or more streamlined designs, when developing their next-generation devices.
To collect an ample amount of light and increase the full well capacity despite the minute pixel sizes, Samsung has incorporated its advanced ISOCELL Plus and Smart-ISO technologies, especially optimized for 0.7μm. ISOCELL Plus retains the received light with a wall-like structure around the pixel while Smart-ISO makes full use of the incoming light by intelligently adjusting the ISO accordingly for optimal exposure.
In the latest 0.7μm products to be introduced later this year, Samsung will start rolling out an enhanced pixel technology, ISOCELL 2.0, which allows excellent performance despite the challenges with decreasing pixel sizes. The new technology further enhanced the wall structure between cells, resulting in added light sensitivity of up to 12 percent compared to the current ISOCELL Plus technology.
The New 0.7μm Lineup;
- ISOCELL HM2 is Samsung’s third 108Mp image sensor following the HMX and HM1. The new 108Mp-sensor is around 15-percent smaller than the 0.8μm-based predecessors, and reduces the height of the camera module by 10 percent. The HM2 features Super PD, a faster and more effective phase detecting auto focus solution, and like the HM1, comes with a nine-pixel binning technology as well as 3x lossless zoom.
- ISOCELL GW3 is a 64Mp-image sensor optimized for mainstream devices. Thanks to the smaller pixel size, the GW3’s optical size is nearly identical to that of Samsung’s 0.8μm 48Mp image sensor. In addition to Tetracell and Smart-ISO technologies that help the sensor take bright images with high color fidelity, the GW3 is ideal for active lifestyles, featuring gyro-based electronic image stabilization (EIS) for sharper still photos and steadier videos. The image sensor supports video recording at up to 4K resolution at 60 frames-per-second (fps).
- ISOCELL GM5 is a versatile 48Mp-image sensor designed for use in telescoping or ultra-wide angle cameras. When used as a 5x optical telescoping sensor for folded-zoom, the GM5 takes full advantage of the compact 0.7μm pixel size that minimizes the camera bulge. For ultra-wide shots, the GM5 supports high-speed full-HD recording at 480fps. The sensor also offers a staggered-HDR feature, a faster and more power-efficient HDR technology that expedites image processing by sending a readout of long, medium, and short exposures of each row of pixels respectively to the mobile processor. As the readout is performed based on Tetracell’s 1.4μm two-by-two pixels, rather than at the individual 0.7μm-pixel level, staggered-HDR can provide brighter and clearer images with less noise.
- ISOCELL JD1 is the industry’s smallest 32Mp-image sensor at 1/3.14-inches, making it an ideal solution for smartphones with bezel-less displays that incorporate a hole-in-active-area or motorized pop-up mechanism for the front-facing camera. Even with 32-million pixels to capture a highly detailed selfie, the camera sits comfortably under the display as the height of the sensor’s camera module is comparable to those of 0.9μm 20Mp or 1.0μm 16Mp sensors. Like the GM5, the JD1 is also the one the first ISOCELL image sensors to offer staggered-HDR.
Samsung ISOCELL HM2, GW3 and JD1 are currently in mass production, and the company is sampling GM5.
# # #
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com .
# # #
* Samsung first announced its ISOCELL technology in 2013, which reduces color crosstalk between pixels by placing a physical barrier, allowing small-sized pixels to achieve higher color fidelity. Based on this technology, Samsung introduced the industry’s first 1.0um-pixel image sensor in 2015 and a 0.9-pixel sensor in 2017. In June 2018, Samsung introduced an upgraded pixel isolation technology, the ISOCELL Plus.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200915005521/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release
Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
